The EUSA Pharma product portfolio focuses on areas of high unmet medical need across a range of therapy areas.


A rare disease is defined as that which affects less than 5 in 10,000 of the general population. There are between 6,000 and 8,000 known rare diseases and around five new rare diseases are described in medical literature each week. EUSA Pharma is committed to supporting treatment for patients with these conditions, who are often underserved in terms of access to effective therapies.


Sylvant® is currently licensed in EU, US and other countries worldwide including Canada, Korea and Mexico and is an interleukin-6 (IL-6) antagonist indicated for the treatment of patients with idiopathic multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. By binding to the IL-6 ligand, Sylvant® therefore blocks the signalling cascade that would lead to proliferation of immune cells.


Cancer remains among the leading causes of death worldwide. EUSA Pharma helps physicians and patients continue the fight against cancer by providing advanced treatment options.


Qarziba® is currently licensed in the EU for the treatment of high risk neuroblastoma, a rare form of cancer arising from neural crest cells, in patients aged 12 months and above. The molecule is a monoclonal chimeric antibody that binds to the GD2 antigen on neuroblastoma cells, and activates an immune response that targets these cancer cells.


Fotivda® is a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI): an oral, once-daily inhibitor of all three vascular endothelial growth factor (VEGF) receptors. Fotivda® is indicated in the EU for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naīve following disease progression after one prior treatment with cytokine therapy for advanced RCC.


Treating the underlying disease is of critical importance; however, therapies are often accompanied by treatment-limiting side effects. EUSA Pharma helps to ease these effects by providing a range of supportive care products to help patients on this difficult journey.


Caphosol® is indicated for the treatment and prevention of oral mucositis, a complication of cancer treatment (including radiation and chemotherapy). It contains a high concentration of phosphate and calcium ions to lubricate the mucosa of the mouth, tongue and oropharynx and help maintain the integrity of the oral cavity. Caphosol® is available as ampules or in dispersible form.